Sarepta Therapeutics Inc. | Ownership
Companies that own Sarepta Therapeutics Inc.
Fidelity Management & Research Co.
7,914,776
11.91%
1,049,198
0.11%
06/30/2018
The Vanguard Group, Inc.
5,177,380
7.79%
132,610
0.02%
06/30/2018
T. Rowe Price Associates, Inc.
4,495,963
6.77%
1,097,796
0.09%
06/30/2018
BlackRock Fund Advisors
3,112,606
4.68%
-1,188,125
0.02%
06/30/2018
Fidelity (Canada) Asset Management ULC
2,164,514
3.26%
1,502,051
0.45%
06/30/2018
FIAM LLC
1,835,103
2.76%
127,610
0.5%
06/30/2018
Fred Alger Management, Inc.
1,558,077
2.35%
-81,788
0.82%
06/30/2018
SSgA Funds Management, Inc.
1,467,473
2.21%
-761,515
0.02%
06/30/2018
Jennison Associates LLC
1,213,899
1.83%
-113,104
0.14%
06/30/2018
Adage Capital Management LP
1,056,611
1.59%
956,611
0.32%
06/30/2018
| Address |
215 First Street
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.sareptatherapeutics.com |
| Updated |
07/08/2019 |
| Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA. |
